142 related articles for article (PubMed ID: 38171145)
1. Plasmodium falciparum topoisomerases: Emerging targets for anti-malarial therapy.
Dar A; Godara P; Prusty D; Bashir M
Eur J Med Chem; 2024 Feb; 265():116056. PubMed ID: 38171145
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Purification and characterization of Plasmodium berghei DNA topoisomerases I and II: drug action, inhibition of decatenation and relaxation, and stimulation of DNA cleavage.
Riou JF; Gabillot M; Philippe M; Schrevel J; Riou G
Biochemistry; 1986 Apr; 25(7):1471-9. PubMed ID: 3011062
[TBL] [Abstract][Full Text] [Related]
4. A small-molecule inhibitor of the DNA recombinase Rad51 from
Vydyam P; Dutta D; Sutram N; Bhattacharyya S; Bhattacharyya MK
J Biol Chem; 2019 May; 294(20):8171-8183. PubMed ID: 30936202
[TBL] [Abstract][Full Text] [Related]
5. A tale of topoisomerases and the knotty genetic material in the backdrop of Plasmodium biology.
Singh P; Rani K; Gotmare A; Bhattacharyya S
Biosci Rep; 2022 Jun; 42(6):. PubMed ID: 35699968
[TBL] [Abstract][Full Text] [Related]
6. Exploring anti-malarial potential of FDA approved drugs: an in silico approach.
Ramakrishnan G; Chandra N; Srinivasan N
Malar J; 2017 Jul; 16(1):290. PubMed ID: 28720135
[TBL] [Abstract][Full Text] [Related]
7. Isolation and structure elucidation of a steroidal moiety from
Pradhan D; Biswasroy P; Sahu DK; Ghosh G; Rath G
J Biomol Struct Dyn; 2023 Jul; 41(11):4993-5006. PubMed ID: 35585777
[TBL] [Abstract][Full Text] [Related]
8. Apicoplast Import Protein Tic20 A Promising Therapeutic Molecular Target for Plasmodium falciparum: An In Silico Approach for Therapeutic Intervention.
C P K Srimath-Tirumala-Peddinti R; Kusuma SS; Nammi D; Neelapu NRR
Infect Disord Drug Targets; 2017; 17(3):199-222. PubMed ID: 28595540
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Plasmodium falciparum proliferation in vitro by antisense oligodeoxynucleotides against malarial topoisomerase II.
Noonpakdee W; Pothikasikorn J; Nimitsantiwong W; Wilairat P
Biochem Biophys Res Commun; 2003 Mar; 302(4):659-64. PubMed ID: 12646219
[TBL] [Abstract][Full Text] [Related]
10. Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases.
Singh S; Pandey VP; Yadav K; Yadav A; Dwivedi UN
Curr Protein Pept Sci; 2020; 21(11):1103-1142. PubMed ID: 32951576
[TBL] [Abstract][Full Text] [Related]
11. Double-drug development against antioxidant enzymes from Plasmodium falciparum.
Biot C; Dessolin J; Grellier P; Davioud-Charvet E
Redox Rep; 2003; 8(5):280-3. PubMed ID: 14962365
[TBL] [Abstract][Full Text] [Related]
12. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
Tse-Dinh YC
Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II Poisons: Converting Essential Enzymes into Molecular Scissors.
Vann KR; Oviatt AA; Osheroff N
Biochemistry; 2021 Jun; 60(21):1630-1641. PubMed ID: 34008964
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II inhibitors induce cleavage of nuclear and 35-kb plastid DNAs in the malarial parasite Plasmodium falciparum.
Weissig V; Vetro-Widenhouse TS; Rowe TC
DNA Cell Biol; 1997 Dec; 16(12):1483-92. PubMed ID: 9428797
[TBL] [Abstract][Full Text] [Related]
15. Cleavage of DNA induced by 9-anilinoacridine inhibitors of topoisomerase II in the malaria parasite Plasmodium falciparum.
Auparakkitanon S; Wilairat P
Biochem Biophys Res Commun; 2000 Mar; 269(2):406-9. PubMed ID: 10708566
[TBL] [Abstract][Full Text] [Related]
16. Manipulating Eryptosis of Human Red Blood Cells: A Novel Antimalarial Strategy?
Boulet C; Doerig CD; Carvalho TG
Front Cell Infect Microbiol; 2018; 8():419. PubMed ID: 30560094
[TBL] [Abstract][Full Text] [Related]
17. 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum.
Kumari M; Chandra S; Tiwari N; Subbarao N
BMC Struct Biol; 2016 Aug; 16():12. PubMed ID: 27534744
[TBL] [Abstract][Full Text] [Related]
18.
Singh P; Tabassum W; Fangaria N; Dey S; Padhi S; Bhattacharyya MK; Arun Kumar K; Roy A; Bhattacharyya S
Microbiol Spectr; 2023 Jun; 11(3):e0498022. PubMed ID: 37212694
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of the antiplasmodial activity of Hsp90 inhibitors.
Murillo-Solano C; Dong C; Sanchez CG; Pizarro JC
Malar J; 2017 Jul; 16(1):292. PubMed ID: 28724415
[TBL] [Abstract][Full Text] [Related]
20. Radicicol confers mid-schizont arrest by inhibiting mitochondrial replication in Plasmodium falciparum.
Chalapareddy S; Bhattacharyya MK; Mishra S; Bhattacharyya S
Antimicrob Agents Chemother; 2014 Aug; 58(8):4341-52. PubMed ID: 24841259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
